Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100043
Funder
Australian Research Council
Funding Amount
$330,000.00
Summary
Development of an ultra-high speed spinning disk confocal micro-particle image velocimetry (PIV) platform for the investigation of cardiovascular disease . This facility will establish a microscope system specifically designed to investigate the function of blood cells in the context of cardiovascular diseases such as heart attack and stroke.
Heparin-induced Thrombocytopenia And Thrombosis: Better Understanding Of Pathogenesis And Improving Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$653,137.00
Summary
Heparin, a widely used drug, can cause an adverse effect which results in a fall of the platelet count and the development of serious thrombosis. This drug complication is mediated by an immune mechanism. This proposal aims to provide a better understanding of the disease mechanism. It also aims to develop a new test that will improve the diagnosis, and to produce a novel drug that will effectively suppress the immune reaction and improve the treatment.
Bioreactors for manufacture of human platelets. Blood cell transfusion is a critical part of medicine that is supported by volunteer donors. Unfortunately, the demand for blood cells for transfusion far outstrips supply and therefore new strategies are required for manufacture of blood cells. This project will lead to the development of technology for manufacture of human platelets from stem cells. The systems devised will be applicable to a broad range of other blood cell types.
Mimetics and small chemical compounds for hemopoietic stem cell mobilisation. This project will result in the design and synthesis of new chemical compounds that could be used clinically to help collect blood stem cells for bone marrow transplantation. For patients this will mean more effective and less painful ways to collect stem cells and better transplant outcomes. There is a large, ongoing international market for this type of drug and likelihood of significant financial benefit.
Autoimmune-based thrombocytopenia can be a life-threatening adverse event associated with viral load, surgery, drug therapies or the use of the anticoagulant, heparin. This grant will define mechanisms of anti-platelet antibody-dependent platelet activation and assess shedding of platelet-specific glycoprotein (GP)VI as an immediate consequence of this activation, provide a new strategy for evaluating risk of thrombosis in HIT.